Dentium KRX:145720KOSPI
덴티움 · Korean news coverage and regulatory filings, organized.
Articles, 24h1
Articles, 7 days1
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, Dentium reported revenue of ₩89.3bn, up 8.6% year on year, and operating profit of ₩14.7bn. Dentium (덴티움) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Sep 15 with 1 article. It was most often mentioned alongside Orum Therapeutics, Nextbiomedical and Qurient.
Dentium quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩89.3bn | +8.6% | ₩14.7bn | ₩13.9bn |
| Q1 2026 | ₩71.4bn | -7.1% | ₩15.9bn | ₩17.1bn |
| Q4 2025 derived | ₩109bn | -8.1% | ₩26.5bn | −₩5.0bn |
| Q3 2025 | ₩78.2bn | -17.4% | ₩12.5bn | ₩3.9bn |
| Q2 2025 | ₩82.3bn | -26.3% | ₩15.5bn | ₩4.7bn |
| Q1 2025 | ₩76.8bn | -7.1% | ₩9.6bn | ₩12.7bn |
| Q4 2024 derived | ₩119bn | -4.4% | ₩27.2bn | ₩20.7bn |
| Q3 2024 | ₩94.7bn | +1.0% | ₩24.4bn | ₩14.8bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Dentium top stories 2 weeks, by number of outlets
- 1